NasdaqGS - Nasdaq Real Time Price USD

Ironwood Pharmaceuticals, Inc. (IRWD)

Compare
4.9000 -0.1400 (-2.78%)
At close: August 27 at 4:00 PM EDT
Loading Chart for IRWD
DELL
  • Previous Close 5.0400
  • Open 4.9850
  • Bid 4.8600 x 200
  • Ask 4.9200 x 600
  • Day's Range 4.8550 - 5.0800
  • 52 Week Range 3.7900 - 15.7000
  • Volume 1,145,929
  • Avg. Volume 2,339,900
  • Market Cap (intraday) 782.721M
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 61.25
  • EPS (TTM) 0.0800
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.50

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

www.ironwoodpharma.com

267

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IRWD

View More

Performance Overview: IRWD

Trailing total returns as of 8/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IRWD
57.17%
S&P 500
17.95%

1-Year Return

IRWD
46.97%
S&P 500
27.69%

3-Year Return

IRWD
62.48%
S&P 500
25.86%

5-Year Return

IRWD
44.88%
S&P 500
95.45%

Compare To: IRWD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IRWD

View More

Valuation Measures

Annual
As of 8/27/2024
  • Market Cap

    782.72M

  • Enterprise Value

    1.32B

  • Trailing P/E

    61.25

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.92

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.29

  • Enterprise Value/EBITDA

    10.87

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.30%

  • Return on Assets (ttm)

    14.93%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    400.56M

  • Net Income Avi to Common (ttm)

    9.21M

  • Diluted EPS (ttm)

    0.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    105.52M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    97.4M

Research Analysis: IRWD

View More

Company Insights: IRWD

Research Reports: IRWD

View More

People Also Watch